5 Stocks Insiders Love Right Now
I would avoid IMAX or look for short-baized trades if it fails to hold that near-term breakout over $25.12 to $25.34 a share, and then drops back below its 50-day at $22.50 and 200-day at $21.58 with high volume. If we get that action, then look for IMAX to trend back below $20 a share. Synageva BioPharma
In the biotechnology and drugs complex, insiders are loading up on Synageva BioPharma (GEVA) , which is focused on the discovery, development and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. Insiders are buying this stock into some big-time strength here, since shares are up over 80% so far in 2012.
Synageva BioPharma has a market cap of $1.04 billion and an enterprise value of $903 million. This stock trades at a premium valuation, with a price-to-sales of 235.20 and a price-to-book of 6.85. Its estimated growth rate for this year is 78.6%, and for next year it's pegged at -51.10%. This is a cash-rich company, since the total cash position on its balance sheet is $138.92 million, and its total debt is zero.